Similar Search Results

Innovation Incentives in the Pharmaceutical Sector : Re-thinking Competition and Public Policy?

Maier-Rigaud, Frank P.; Lauer, Robert; Robles, Laura - 2021

pandemic; and more specifically for competition authorities, as demonstrated for example by the role innovation played in the … innovation debate, notably in the pharmaceutical industry, by giving an overview on firm and market-level incentives to carry out … research and development (R&D). Understanding these innovation incentives is relevant for a proper competition assessment where …

Persistent link: https://www.econbiz.de/10013227948

Making Do in Making Drugs : Innovation Policy and Pharmaceutical Manufacturing

Price II, W. Nicholson - 2016

far behind the innovative manufacturing found in other industries. This lack of innovation in drug manufacturing stands in … stark contrast to the innovation present in drug discovery. Drug discovery is the focus of a calibrated innovation policy … dollars and in human lives. This article addresses the previously underappreciated role of manufacturing in innovation studies …

Persistent link: https://www.econbiz.de/10014038452

Taiwan's pharmaceuticals : a failure of the sectoral system of innovation?

Hu, Mei-chih; Hung, Shih-Chang - In: Technological forecasting & social change : an … 88 (2014), pp. 162-176

Persistent link: https://www.econbiz.de/10010483232

Institutioneller Wandel in Innovationssystemen : eine vergleichende Untersuchung der japanischen Pharma- und Halbleiterforschung

Philipsenburg, Gisela - 2005 - 1. Aufl.

Persistent link: https://www.econbiz.de/10002553495

Public subsidies for R&D and public sector pharmaceutical innovation

Kourouklis, Dimitrios - In: Applied economics 53 (2021) 32, pp. 3759-3777

Persistent link: https://www.econbiz.de/10012589537

Essays on Government Policy and Pharmaceutical Innovation - Dissertation Executive Summary

Blume-Kohout, Margaret - 2010

New drug therapies may deliver many social and economic benefits, but current levels of innovation across diseases may …

Persistent link: https://www.econbiz.de/10014195493

Mapping the strength of sectoral innovation system in the Nigerian pharmaceutical industry : empirical evidence

Ayo-Lawal, Rachael Aderonke; Adelowo, Caleb Muyiwa; … - In: African journal of science, technology, innovation and … 15 (2023) 2, pp. 198-210

Persistent link: https://www.econbiz.de/10014251267

Calculating the Costs and Benefits of Advance Preparations for Future Pandemics

Glennerster, Rachel; Snyder, Christopher M.; Tan, … - National Bureau of Economic Research - 2022

The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of...

Persistent link: https://www.econbiz.de/10013435127

An Optimal Mechanism to Fund the Development of Vaccines Against Emerging Epidemics

Snyder, Christopher M.; Hoyt, Kendall; Gouglas, Dimitrios - National Bureau of Economic Research - 2022

We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding cost-reimbursement contracts, requiring fixed-price...

Persistent link: https://www.econbiz.de/10013462668

Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Michaeli, Daniel; Michaeli, Christoph T.; Albers, Sebastian - In: The European journal of health economics 25 (2024) 6, pp. 979-997

Persistent link: https://www.econbiz.de/10014633366

1
2
3
4
5
6
7
8
9
10
Next
Last